- Home
- AUTL
as 05-17-2024 4:00pm EST
$.
+$.
+.%
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.2B | IPO Year: | 2018 |
| Target Price: | $9.33 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $7.45 | Next Earning Date: | 05-16-2024 |
| Revenue: | $10,497,000 | Revenue Growth: | 40.22% |
| Revenue Growth (this year): | 2505.95% | Revenue Growth (next year): | 173.41% |
Share on Social Networks:
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
2 days ago
Q1 2024 Autolus Therapeutics PLC Earnings Call
MT Newswires
2 days ago
Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises
GlobeNewswire
3 days ago
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
5 days ago
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
MT Newswires
6 days ago
Autolus Therapeutics Announces Delay of Q1 Earnings Release
GlobeNewswire
7 days ago
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
Simply Wall St.
24 days ago
Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
GlobeNewswire
25 days ago